Until now, no non-invasive method has existed for the comprehensive staging and classification of arterial plaque – even though this approach represents the paradigm that is used for early diagnosis and treatment of breast, colon, and lung cancer. Instead of directly examining heart disease, or atherosclerosis, current approaches in cardiovascular medicine rely upon indirect markers of disease, such as symptoms, cholesterol, and other factors known as surrogates.

Join cardiologist and Cleerly CEO, Dr. James Min, as he shares about the industry’s first atherosclerotic plaque burden staging system and how we can take a page from the oncology playbook to redefine the standard of care in cardiology. Learn how providers can use these stages and thresholds, which are based on evidence from coronary angiography stenosis and fractional flow reserve (FFR) data, to determine precision medical therapy based upon an individual's atherosclerotic phenotype.


Webinar discussion points include:

- How does the successful staging paradigm used in oncology benefit cardiology?
- What is the relationship of atherosclerosis to stenosis severity and ischemia?
- What are the plaque stages of the proposed CCTA plaque volume staging system?
- What is the clinical utility for patient diagnosis and management of coronary artery disease?
- What are the next steps for implementing this staging system into clinical practice?

Speakers:

James Min, MD, Chief Executive Officer and Co-Founder of Cleerly

James Earls, MD, Chief Medical Officer of Cleerly

References to a specific product, process, or service by speakers this webinar series do not constitute or imply an endorsement by the Society of Cardiovascular Computed Tomography. The views and opinions expressed in do not necessarily reflect those of the Society of Cardiovascular Computed Tomography.

свернуть